All In Biotech

Free tool

FAERS Monitor: Granix

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125294 or its brand name (Granix, Tbo-Filgrastim). Reports on generic versions are filed under their own applications.

Reports

871

Serious

542

62% of reports

Hospitalization

274

Death reported

129

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death79
  • fatigue70
  • white blood cell count decreased53
  • diarrhoea44
  • drug ineffective40
  • nausea40
  • neutropenia40
  • off label use40
  • pyrexia32
  • asthenia30
  • febrile neutropenia29
  • pneumonia28
  • cytokine release syndrome27
  • thrombocytopenia24
  • headache23

Reports by year received

View as table
YearReports
201423
201546
201658
201762
2018113
2019115
2020120
2021130
202261
202354
202437
202525
202627

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,288 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cytokine release syndromeSignal2732.522.4794
white blood cell count decreasedSignal5311.89.1516
febrile neutropeniaSignal2910.67.4242
neutropeniaSignal407.15.2205
thrombocytopeniaSignal245.23.577
pyrexiaSignal322.21.621
deathSignal792.21.854
fatigueSignal702.21.745
pneumoniaSignal282.11.515
asthenia301.91.413
diarrhoea441.61.211
nausea401.20.91
off label use401.10.80
headache230.90.60
drug ineffective400.70.54

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.